About Xanthus Pharmaceuticals
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule therapeutic candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialisation. The Company is applying its expertise to advance its current pipeline to address significant unmet medical need in oncology and autoimmune diseases. Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec.
Xanthus Pharmaceuticals Frequently Asked Questions (FAQ)
When was Xanthus Pharmaceuticals founded?
Xanthus Pharmaceuticals was founded in 2001.
Where is Xanthus Pharmaceuticals's headquarters?
Xanthus Pharmaceuticals's headquarters is located at 300 Technology Square, Cambridge.
What is Xanthus Pharmaceuticals's latest funding round?
Xanthus Pharmaceuticals's latest funding round is Acquired.
How much did Xanthus Pharmaceuticals raise?
Xanthus Pharmaceuticals raised a total of $63.8M.
Who are the investors of Xanthus Pharmaceuticals?
Investors of Xanthus Pharmaceuticals include Sarossa Capital, Tekla Capital Management, Still River Funds, GeneChem Management, Kestrel Management and 9 more.
Who are Xanthus Pharmaceuticals's competitors?
Competitors of Xanthus Pharmaceuticals include Arena Pharmaceuticals, Evotec SE, Constellation Pharmaceuticals, Kiadis Pharma, Actinobac Biomed and 7 more.
Compare Xanthus Pharmaceuticals to Competitors
Can-Fite BioPharma is a biopharmaceutical company focused on the discovery and clinical development of proprietary drugs for inflammatory, liver, and metabolic diseases. The company's main offerings include oral drugs that target the A3 adenosine receptor to modulate inflammatory and cancer pathways, with a pipeline of drug candidates in Phase II and Phase III clinical trials. Can-Fite's products are designed to have anti-inflammatory and anti-cancer effects by binding to the A3AR and affecting the NF-kB and Wnt signal transduction pathways. It is based in Petach-Tikva, Israel.
United Biomedical is a multinational biopharmaceutical company that operates in the healthcare and pharmaceutical industry. The company primarily focuses on the development of diagnostics and immunotherapeutics, with a product range that includes synthetic peptide-based vaccines and diagnostics, therapeutic monoclonal antibodies, and contract manufacturing services for the biopharmaceutical industry. United Biomedical primarily serves the healthcare sector, with a particular focus on chronic and infectious diseases. It is based in Hauppauge, New York.
SBIO is focused on the discovery and development of small molecule oncology drugs.
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
AnaMar Medical is a biopharmaceutical company focused on developing novel medicines for the treatment of fibrotic diseases. Their main product is a highly selective, peripheral-acting receptor antagonist designed to prevent, heal, and slow organ scarring caused by fibrotic conditions. The company's research and development efforts are geared towards advancing this medicine through clinical trials, with a current focus on skin and lung manifestations of systemic sclerosis. It was founded in 1998 and is based in Sweden.
MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.